Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2009
06/30/2009US7553829 Administering delta 5-androstene-3 beta-ol-7,17 dione and metabolizable precursors thereof, such as the 3-beta acetate
06/30/2009US7553828 Treating antibiotic resistant infections such as Escherichia coli, Staphylococcus aureus, E. faecalis
06/30/2009US7553827 Transdiscal administration of cycline compounds
06/30/2009US7553826 Cytarabine monophosphate prodrugs
06/30/2009US7553825 2-Amino,6-cyclopropyl,9-((bis(alkoxycarbonylalkylamino-)phosphinyl)-methoxyethyl-)purine;viricides; papilloma virus; urogental disorders; antiapoptosis; prodrugs; oral drug delivery; bioavailability
06/30/2009US7553823 C-pyrazole A2A receptor agonists
06/30/2009US7553822 Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene
06/30/2009US7553821 Methods for selectively modulating survivin apoptosis pathways
06/30/2009US7553820 Mevalonic acid derivatives
06/30/2009US7553819 glycerol cyclic pyruvate derivates; inhibit the binding of an immobilized D-proline derivative to serum amyloid P componen; amyloidosis; Alzheimers disease; maturity onset diabetes mellitus
06/30/2009US7553818 Combination therapy for effecting weight loss and treating obesity
06/30/2009US7553817 Ribose; enhancing ATP recovery and synthesis; increasing exercise capacity
06/30/2009US7553815 Therapeutic use
06/30/2009US7553646 Synthesis of racemic and enantiomers of modafinil via microbial oxidation-amidation transformation; subjecting benzhydrylsulfanyl carboxylic acid to an oxidation-amidation; attention deficit hyperactivity disorder and drug addiction
06/30/2009US7553503 Phyto-nutraceutical synergistic composition for Parkinson's Disease
06/30/2009US7553500 6-phenyl-5-(4-(2-pyrrolidin-1-ylethoxy)phenyl)-5,6,7,8 -tetrahydronaphthalen-2-ol (laxofoxifene); a prodrug with a glidant, disintegrant, lubricant and diluent/filler in given amounts; unit dosage forms, including low dosage forms; selective estrogen receptor modulators
06/30/2009US7553499 Sustained release tablet containing indapamide
06/30/2009US7553498 Gastrointestinal disorders; anitulcer agents; mixture with surfactants and distingrat; cellulose ether enteric coating
06/30/2009US7553496 VEGF-A as an inhibitor of angiogenesis and methods of using same
06/30/2009US7553493 Chlamydia flagellar protein antigen
06/30/2009US7553492 Gene overexpression/underexpression; antibodies; drug screening; kits
06/30/2009US7553482 Preventing atherosclerotic disease, bone disorders by administering iron(III) oxide hydroxide-carbohydrate complexes; for reducing the calcium phosphate product, calcium level in the blood; side effect reduction; controlling blood metal concentration
06/30/2009US7553479 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
06/30/2009CA2554696C Androgen receptor modulators
06/30/2009CA2527365C Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
06/30/2009CA2510964C Therapeutic phenoxyalkylfurans and intermediates therefor
06/30/2009CA2473076C Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones
06/30/2009CA2459399C Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
06/30/2009CA2441096C Nicotinic receptor agonists for the treatment of inflammatory diseases
06/30/2009CA2422356C Suppository of retaining in lower region of rectum
06/30/2009CA2407468C Hydrates and crystals of a neuraminic acid compound
06/30/2009CA2406833C Effervescent granules and methods for their preparation
06/30/2009CA2391625C Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan
06/30/2009CA2373939C Generation of therapeutic microfoam
06/30/2009CA2368812C Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy
06/30/2009CA2330447C N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
06/30/2009CA2307111C Novel pyridazine derivatives and drugs containing the same as the active ingredient
06/30/2009CA2295101C Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
06/30/2009CA2222453C Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
06/30/2009CA2203480C Interferon conjugates
06/30/2009CA2188319C Coated products with potent anti-hiv and antimicrobial properties
06/30/2009CA2158662C Sustained release veterinary composition
06/30/2009CA2143486C Method of improving the immune response
06/30/2009CA2095521C Hepatitis c virus asialoglycoproteins
06/25/2009WO2009079637A1 Tetrahydroisoquinoline derivatives
06/25/2009WO2009079630A1 4-imidazolidinones as kv1.5 potassium channel inhibitors
06/25/2009WO2009079624A1 4-imidazolidinones as kv1.5 potassium channel inhibitors
06/25/2009WO2009079593A1 Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
06/25/2009WO2009079562A2 Compositions and methods for treating and preventing skeletal muscle deficiencies
06/25/2009WO2009079547A1 Quinazoline anhydrate forms
06/25/2009WO2009079544A1 Materials and methods for treatment of pathological ocular vascular proliferation
06/25/2009WO2009079541A1 Quinazoline ditosylate anhydrate forms
06/25/2009WO2009079521A1 Pharmaceutical composition
06/25/2009WO2009079518A1 Pharmaceutical composition
06/25/2009WO2009079490A1 Process and intermediates for the synthesis of heterocyclic substituted piperazines with cxcr3 antagonist activity
06/25/2009WO2009079412A2 Reverse transcriptase inhibitors
06/25/2009WO2009079405A2 Assessing treatment compliance
06/25/2009WO2009079392A1 Amidine-containing compounds useful as muscarinic receptor antagonists
06/25/2009WO2009079391A1 Benzofuran anilide histone deacetylase inhibitors
06/25/2009WO2009079373A2 Inhibitors of calcium-activated chloride channels
06/25/2009WO2009079353A1 Triazole-containing macrocyclic hcv serine protease inhibitors
06/25/2009WO2009079352A1 Macrocyclic oximyl hepatitis c serine protease inhibitors
06/25/2009WO2009079345A1 Process for recovering flunixin from pharmaceutical compositions
06/25/2009WO2009079225A1 Cyclopropyl amine derivatives
06/25/2009WO2009079126A1 Topical compositions comprising non-proteogenic amino acids and methods of treating skin
06/25/2009WO2009079011A1 Benzimidazoles and analogs as rho kinase inhibitors
06/25/2009WO2009079008A1 Benzopyrans and analogs as rho kinase inhibitors
06/25/2009WO2009079007A1 Stem-like cells and method for reprogramming adult mammalian somatic cells
06/25/2009WO2009079000A1 Imidazolopyrimidine modulators of trpv1
06/25/2009WO2009078999A1 Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
06/25/2009WO2009078992A1 Linear tricyclic compounds as p38 kinase inhibitors
06/25/2009WO2009078988A1 Sinomenine derivatives and processes for their synthesis
06/25/2009WO2009078983A1 Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
06/25/2009WO2009078981A2 Ppar-delta ligands and methods of their use
06/25/2009WO2009078978A2 Compositions containing polyglycidol-based polymers and uses thereof
06/25/2009WO2009078956A1 Pharmaceutical compositions
06/25/2009WO2009078934A1 Mineralocorticoid receptor modulators
06/25/2009WO2009078813A1 Method of forming oseltamivir and derivatives thereof
06/25/2009WO2009078798A1 Pharmaceutically acceptable salts of methyl (3-{ [[3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl] (3- morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
06/25/2009WO2009078794A1 Compounds for use in the treatment of cancer
06/25/2009WO2009078783A1 Breast cancer treatment and treatment prediction
06/25/2009WO2009078782A1 Method and means for producing bronchorelaxation
06/25/2009WO2009078746A1 Substituted 3 -hydroxypyridines and pharmaceutical compositions thereof
06/25/2009WO2009078586A1 Composition for prevention and treatment of cancer containing phenyl-amino-thiazolone derivatives inhibiting activity of protein phosphatases or pharmaceutically acceptable salts thereof as an active ingredient
06/25/2009WO2009078498A1 Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
06/25/2009WO2009078481A1 Bicyclic heterocyclic derivative
06/25/2009WO2009078474A1 An agent for reducing a side effect of an anticancer drug
06/25/2009WO2009078444A1 Preventive or therapeutic agent for inflammatory bowel disease
06/25/2009WO2009078432A1 1-alkyl-4-amino-1h-pyrazole-3-carboxamide compound
06/25/2009WO2009078423A1 Fused tricyclic compound having aldose reductase inhibitory activity
06/25/2009WO2009078366A1 α-LIPOIC ACID NANOPARTICLE AND METHOD FOR PRODUCING THE SAME
06/25/2009WO2009078040A2 Compounds inducing reperfusion in ischaemic tissues
06/25/2009WO2009078039A2 Compound inducing angiogenesis response in ischaemic tissues
06/25/2009WO2009078034A2 Orally disintegrating tablets of ropinirole hydrochloride
06/25/2009WO2009077990A1 Aminotriazole derivatives as alx agonists
06/25/2009WO2009077989A1 5-aminocyclylmethyl-oxazolidin-2-one derivatives
06/25/2009WO2009077960A1 Novel compounds useful in therapeutic and cosmetic methods
06/25/2009WO2009077954A1 Aminopyrazole derivatives
06/25/2009WO2009077858A2 Hemioxalate salt of eletriptan
06/25/2009WO2009077844A2 Inhibitors of biofilm formation of gram-positive and gram-negative bacteria
1 ... 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 ... 7860